Pentablock Copolymer Dexamethasone Nanoformulations Elevate MYOC: In Vitro liberation, Activity and Safety in Human Trabecular Meshwork Cells

Abstract

The treatment of HTM cells using DEX-PB-NPs were analyzed in this study. The in vitro cell-based system developed here is a valuable tool for determining the safety and effects of steroids released from polymeric NPs.

The relationship between outflow resistance and trabecular meshwork stiffness in mice

“…Details of mouse numbers in each cohort and the injected eyes are listed in Table 1 . A previous in vitro study showed that DEX release from the particles typically lasted for 3 months, with about 20% of DEX released in the first 2 days 12 .…”

“…All PB-NPs were provided by the lab of one co-author (A.K.M.) Information regarding the synthesis of copolymers, formulation of DEX-encapsulated PB nanoparticles and in vitro drug release profile have been described in detail in a recent publication 12 . Further, the safety of both PB-NPs and DEX-PB-NPs were evaluated in in vitro cell culture system.…”

“…Further, the safety of both PB-NPs and DEX-PB-NPs were evaluated in in vitro cell culture system. Briefly, DEX-PB-NPs were formulated by an oil-in-water single emulsion solvent evaporation method as described previously 12 and stored at -20 °C until further use. The particle size was in the range of 109 ± 3.77 nm.…”

“…Agrahari et al . 12 have recently developed a method to deliver DEX to human TM cells using DEX-encapsulated pentablock copolymer-based nanoparticles (DEX-PB-NPs). They showed that DEX was released continuously from the PB-NPs over 3 months, with 50% released within the first 6 weeks.…”

Antifibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis

“…Steroid-induced OHT in mice was generated using nanotechnology (Agrahari, Li et al 2017), resulting in a model that closely matched steroid-induced observations in the human condition (decreased outflow facility, increased accumulation of ECM in the TM, and elevated IOP) (Johnson, Bradley et al 1990, Johnson and Knepper 1994, Johnson, Gottanka et al 1997, Clark, Steely et al 2001. The present study further highlights the utility of this mouse model of steroid-induced glaucoma and its translational relevance to the human clinical condition.…”